Latest Research And Development News

Harvest Technology Group reported a reduced net loss of $7.06 million for FY2025 amid restructuring and new funding, while focusing on its remote communications technology segment and launching Project NEON.

ReadyTech reported a solid 7.1% revenue increase in FY25, driven by $15.4 million in new enterprise contracts and a strategic push into AI-enhanced SaaS products. The company’s strong pipeline and AI initiatives set the stage for accelerated growth in FY26 and beyond.

ReadyTech Holdings Limited reported a 7.1% increase in revenue to $121.8 million for FY25 but swung to a $16.1 million loss after tax, driven by a significant impairment and strategic investments. The company completed the acquisition of CouncilWise Pty Ltd, aiming to strengthen its local government software offerings.

MyEco Group Ltd reported an 8.6% revenue increase to $15.7 million in FY25, driven by strong growth in its MyEco® branded products and improved margins. The company cut its net loss by nearly half, supported by operational restructuring and expanding market presence.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.